AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2021. The put-call ratio across all filers is 0.11 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $191,426 | -88.9% | 18,585 | -82.2% | 0.00% | -90.9% |
| Q2 2023 | $1,724,039 | +281.6% | 104,614 | +112.1% | 0.01% | +266.7% |
| Q1 2023 | $451,817 | -59.9% | 49,325 | -68.6% | 0.00% | -57.1% |
| Q4 2022 | $1,125,624 | +332.9% | 157,210 | +203.4% | 0.01% | +600.0% |
| Q3 2022 | $260,000 | -22.2% | 51,809 | +25.2% | 0.00% | -66.7% |
| Q4 2021 | $334,000 | +89.8% | 41,370 | +130.2% | 0.00% | +50.0% |
| Q3 2021 | $176,000 | -49.3% | 17,973 | -73.9% | 0.00% | -60.0% |
| Q3 2020 | $347,000 | +184.4% | 68,820 | +349.0% | 0.01% | +66.7% |
| Q1 2020 | $122,000 | +84.8% | 15,326 | +41.6% | 0.00% | 0.0% |
| Q2 2018 | $66,000 | -26.7% | 10,820 | -1.5% | 0.00% | -40.0% |
| Q4 2017 | $90,000 | -51.1% | 10,982 | -37.4% | 0.01% | -50.0% |
| Q3 2017 | $184,000 | – | 17,531 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,409,289 | $24,815,676 | 12.25% |
| Knoll Capital Management, LLC | 600,000 | $6,180,000 | 6.42% |
| Vivo Capital, LLC | 4,096,428 | $42,193,208 | 4.62% |
| GENDELL JEFFREY L | 5,615,350 | $57,838,105 | 3.29% |
| Tri Locum Partners LP | 983,602 | $10,131,101 | 3.24% |
| Samsara BioCapital, LLC | 967,527 | $9,965,528 | 3.05% |
| MPM BioImpact LLC | 664,224 | $6,841,507 | 1.83% |
| COWEN AND COMPANY, LLC | 2,338,302 | $24,084,510 | 1.68% |
| RTW INVESTMENTS, LP | 7,136,415 | $73,505,075 | 1.55% |
| TANG CAPITAL MANAGEMENT LLC | 1,000,000 | $10,300,000 | 1.45% |